An experimental Ebola vaccine similar to one being developed by GlaxoSmithKline is effective for at least five weeks in lab monkeys but requires boosting with an additional vaccine to extend its protection to 10 months, according to a study published on Sunday. Thomas Geisbert of UTMB works on the VSV-based Ebola vaccine being developed by Profectus. He questioned the practicality of a two-shot vaccine regimen. "You really need a fast-acting single injection vaccine" for protecting a community during an outbreak or preparing first responders and healthcare workers, he said. Only VSV vaccines have been shown to protect lab monkeys when given after infection with Ebola, Geisbert said: "This makes it so much more useful than any of the other vaccines. For outbreaks, it works fast." The article also appears on Fox News and the Huffington Post.